Analysis of the relationship between cancer procoagulant activity and PCNA and Ki-67 expression in cases of common and cellular uterine leiomyomas

Purpose: Histological subtypes of uterine leiomyomas may substantially differ in their cellular biology, including the intensity of synthesis of cancer markers and expression of cell proliferation markers. The present investigation aimed to determine the activity of cancer procoagulant (CP) in subtypes of leiomyomas, including cellular leiomyomas, and to verify whether these activities correlate with immunoexpression of cell proliferation markers: the proliferating cell nuclear antigen (PCNA) and Ki-67.

Materials and methods: Preoperative peripheral venous blood and postoperative tissue material were obtained from 24 women operated on in a tertiary referral academic department. The activity of CP in serum was measured with the use of a coagulative method according to Gordon and Benson, and in tissue homogenates with the use of a spectrophotometric method according to Colucci et al. The control serum values were obtained from 20 healthy women without any gynecological disease, and the control solid tissue values from histologically confirmed postoperative normal reproductive tissues obtained from six patients. PCNA and Ki-67 expression were determined immunohistochemically using monoclonal antibodies.

Results: Both the tissue and serum activity for CP was considerably higher for common leiomyomas and cellular leiomyomas than for control tissues, but did not differ significantly between the leiomyoma subtypes. Intratumor CP activity significantly correlated with PCNA expression but not with Ki-67 expression.

Conclusions: Cellular leiomyomas do not differ substantially in the serum and intratumor CP activity from common leiomyomas. There is a relationship of intratumor CP activity with PCNA expression, a finding which requires further investigation.

Cancer procoagulant (CP); Cellular leiomyoma; Common leiomyoma; Ki-67; PCNA

[1] Gordon S.G., Chellandurai M.: "Non-tissue factor procoagulants in cancer cells". Cancer Metastasis Rev., I 992, 11, 267.

[2] Gordon S.G., Frank、J.J., Lewis B.J.: "Comparison of procoagul ant activities in extracts of normal and malignant human tissue" J. Natl. Cancer Inst., 1979, 62, 773.

[3] Mielicki W.P.: "Biochemistry of cancer procoagulant". Haemostasis, 2001, 31 (suppl. 1), 8.

[4] Gordon S.G.: "Cancer cell procoagulants and their role in maltgnant disease". Se min. 7hromb. He most., 1992, 18, 424.

[5] Lee A. Y.: "Cancer and thromboembolic disease: pathogenic mech anisms". Cancer Treat. Rev., 2002, 28, 137.

[6] Joziwik M., Szajda S.D., Skrzydlewski Z., Joziwik M., Sulkowski S.: "The activity of cancer procoagulant in cases of uterine leiomyomas". Eur. J. Gynaecol. Oneal., 2005, 26, 407.

[7] Buttram V.C. Jr., Reiter R.C.: "Uterine leiomyomata: etiology, symptomatology, and management". Fertil. Steril., 1981, 36, 433.

[8] Schwartz L.B., Zawin M., Carcangiu M.L., Lange R., McCarthy S.: "Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata9". Fertil. Steril., 1998, 70, 580.

[9] Ueda H., Togashi K., Konishi I., Kataoka M.L., Koyama T., Fujiwara T. et al.: "Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds". Radiographics, 1999, 19, S131.

[10] Ferenczy A., Richart R.M., Okagaki T.: "A comparative ultrastructural study of leiomyosarcoma, cellular leiomyoma, and leiomyoma of the uterus". Cancer, 1971, 28, 1004.

[11] Dixon D., Flake G.P., Moore A.B., He H., Haseman J.K., Rismger J.I. et al.: "Cell proliferation and apoptosis in human uterine leiomyomas and myometria". Virchows Arch., 2002, 441, 53.

[12] Zaslawski R., Surowiak P., Dziegiel P., Pretnik L., Zabel M.: "Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki-67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle". Med. Sci. Monit., 2001, 7, 908.

[13] Colucci M., Curatolo L., Donati M.B., Semeraro N.: "Cancer cell procoagulant activity: evaluation by an amidolytic assay". Thromb. Res., 1980, 18, 589.

[14] Gordon S.G., Benson B.: "Analysis of serum cancer procoagulant activity and its possible use as a tumor marker". Thromb. Res., 1989, 56, 431.

[15] Szajda S.D., Joziwik M.，Jozwik M., Zalewska B., Panek G., Sulkowski S. et al.: "Cancer procoagulant activity in serum and neoplastic tissue in cases of cervical and uterine carcinoma". Ginekol. Pol., 2004, 75, 705.

[16] Weiss D.B., Aldor A., Aboulafia Y.: "Erythrocytosis due to erythropoietin- producing uterine fi bromyoma". Am. J. Ob stet. Gynecol., 1975, 122, 358.

[17] Naets J.P., Wittek M., Delwiche F., Kram I.: "Polycythaemia and erythropoietin producing uterine fibromyoma". Scand. J. Haematol.. 1977, 19, 75.

[18] Prosperi E.: "Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control". Prag. Cell Cycle Res., 1997, 3, 193.

[19] Paunesku T., Mittal S., Protic M., Oryhon J., Korolev S.V., Joachimiak A. et al.: "Proliferating cell nuclear antigen (PCNA): ringmaster of the genome". Int. J. Radiat. Biol., 2001, 77, 1007.

[20] Maga G., Hubscher U.: "Proliferating cell nuclear antigen (PCNA): a dancer with many partners". J. Cell Sci., 2003, 116, 3051.

[21] Scholzen T., Gerdes J.: "The Ki-67 protein: from the known and the unknown". J. Cell. Physiol., 2000, 182, 311.

[22] Kir G., Cetiner H., Karateke A., Gurbuz A., Bulbul D.: "Utility of MIB-1 and estrogen and progesterone receptor in distinguishing between endometrial stromal sarcomas and endometrial stromal nodules, highly cellular leiomyomas". Int. J. Gynecol. Cancer., 2005, 15, 337.

[23] Andersen J.: "Factors in fibroid growth". Baillie res Clin. Obstet. Gynaecol., 1998, 12, 225.

[24] Maruo T., Matsuo H., Samoto T., Shimomura Y., Kurachi 0., Gao Z. et al.: "Effects of progesterone on uterine leiomyoma growth and apoptosis". Steroids, 2000, 65, 585.